Skip to main content

Packard Bioscience Enters Protein Array Market With HydroGel Product

NEW YORK, Sept. 26 - Packard Bioscience has launched its HydroGel coated slides for protein microarray applications, marking the company’s first protein array product, the company said on Wednesday.

According to Packard, slides coated with the HydroGel substrate are based on a 3-dimensional polyacrylamide gel technology and offer a safer environment on which proteins can be immobilized.

The substrate choice is “a major consideration for researchers conducting protein microarray experiments,” including antibody screening, protein-protein interaction studies, protein expression profiling, and immunoassays.

Unlike nucleic acids, proteins are particularly sensitive to their immediate environment, and can become inactivated by the material on which they are printed. This inactivation can impair the structure and functionality of a protein, stifling research, the company said.

The commercial availability of the slides “marks a major milestone for Packard and enables us to offer one of the most complete solutions for protein microarray applications available from a single company,” Jocelyn Burke, vice president and general manager of Packard BioChip Technologies, a wholly owned subsidiary of Packard Bioscience Company, said in a statement.

The Scan

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.